Study Shows Coronado Biosciences’ Bcl-2 Inhibitor, Apogossypol, Is More Efficacious, Less Toxic Than Gossypol In Animal Models

January 29th, 2008 | Category: Cancer

Coronado Biosciences Inc. announced the publication of documents demonstrating that the Bcl-2 inhibitor, Apogossypol, effectively killed a variety of cancer cells in vitro while demonstrating less toxicity than Gossypol in vivo in mice.

Published online in Blood (Jan. 17, DOI 10.1182/blood-2007-09-113647) by the Burnham Institute’s president and CEO, John Reed, M.D., Ph.D.

Original post by Women’s Health / Gynecology News From Medical News Today

Share and Enjoy: These icons link to social bookmarking sites where readers can share and discover new web pages.
  • Digg
  • del.icio.us
  • Netvouz
  • DZone
  • ThisNext
  • MisterWong
  • Wists
  • BlinkList
  • Furl
  • IndianPad
  • Netscape
  • Reddit
  • Simpy
  • Spurl
  • StumbleUpon
  • Technorati
Related Articles
  • Inhibitor For Heparanase Has Potential As Cancer Drug
  • Novel Multi-Targeted Kinase Inhibitor, AP24534 Supports Multiple Oncology Indications
  • Pharmacyclics’ Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition Of Tumor Growth In Multiple Types Of Cancer
  • ERMA’s Recommendation To Continue The Use Of Endosulfan In New Zealand Dismays Breast Cancer Network
  • Kosan’s Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit In Phase 1 HER2-Positive Metastatic Breast Cancer Trial

    • No comments yet. Be the first.

    Leave a reply

    You must be logged in to post a comment.